Running title: Hmgcr promoter polymorphisms govern gene expression
INTRODUCTION
Essential hypertension, a major risk factor for cardiovascular diseases, is often associated with dysregulated cholesterol levels (1, 2) . Cholesterol is the precursor of corticosteroids which play a crucial role in blood pressure (BP) regulation (3) . Hence, 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) reductase gene (human: HMGCR, mouse/rat: Hmgcr) that codes for a ~ 97 kDa glycoprotein catalysing the rate-limiting step in the cholesterol biosynthesis pathway is a susceptibility gene for hypertension (4) (5) (6) .
Transcriptome analysis in adrenal glands of two independent genetic rodent models of hypertension viz. spontaneously hypertensive rats (SHR) and blood pressure high (BPH) mice revealed ~2.5 to 3-fold elevated Hmgcr expression as compared to their respective controls [viz. Wistar/Kyoto (WKY) rat and blood pressure low (BPL) mice] (7) . Hmgcr was also over-expressed (by ~2.6-fold) in the liver of BPL mice as compared to BPH.
Interestingly, sequencing of the regulatory regions in the Hmgcr locus (viz. promoter, exons and flanking introns) from BPH, BPL and blood pressure normal (BPN) strains revealed multiple variations in the proximal promoter and coding regions. Two variations in the Hmgcr promoter domain (C-874T and C-470T) altered the binding affinities of transcription factors n-Myc, Max and c-Fos resulting in the differential expression of Hmgcr in these models of essential hypertension (8) . However, the mechanism of regulation of Hmgcr expression in rat models of hypertension (viz. SHR and WKY) has not been explored so far. SHR strain, the most widely used model for essential hypertension, was developed based on a breeding program where elevated BP was used for selection in Wistar rats (9, 10) .
The normotensive control strain for SHR, Wistar/Kyoto (WKY) strain, was also generated in the same breeding program by inbreeding of the original Wistar colony (from which the SHR strain originated) (11) . SHR parallels human essential hypertension with co-morbidities (viz. insulin resistance, left ventricular hypertrophy, hypertriglyceridemia and abdominal obesity) (12) (13) (14) . In the current study, we sequenced the proximal Hmgcr promoter in SHR as well as WKY and discovered three promoter variations [viz. A-405G, C-62T and a 11 bp insertion (-393_-382insTGCGGTCCTCC)]. Next, we assessed the functional impact of these variations by systematic computational and experimental analyses. Our results reveal that A-405G and -393_-382insTGCGGTCCTCC altered the binding affinity of Runx3 and Srebf1 transcription factors and modulated the Hmgcr expression in these rat models of human essential hypertension. Interestingly, intracellular cholesterol level also regulates Hmgcr expression via Runx3 and Srebf1. HMGCR transcript level positively correlated with the transcript level of SREBF1 in various human tissues. In addition, this study for the first time to our knowledge, provides evidence of Hmgcr regulation by Runx3 under basal and cholesterolmodulated conditions.
MATERIALS AND METHODS

Blood pressure QTLs and LOD scores
The information about the blood pressure QTLs along with their LOD scores and all the genes harboured within a particular QTL was retrieved from the Rat Genome Database (15) .
Next, comparative genome analysis of the rat genomic regions with mouse and human genomic regions at the Hmgcr locus was performed using mVISTA (16) . The mVISTA browser uses AVID alignment algorithm that employs global alignment for sequence comparison of the input queries.
Rat strains and tissue samples
All animal procedures were approved by the Institutional Animal Ethics Committee at Indian Institute of Technology Madras and CSIR-Central Drug Research Institute, Lucknow, India.
Male Spontaneously Hypertensive Rats (SHR) and Wistar/Kyoto (WKY) rats (n=6) were obtained from National Laboratory Animal Centre, CSIR-Central Drug Research Institute, Lucknow, India. These animals were housed in polypropylene cages under controlled room temperature at 25 °C on a 12 hr light-dark cycle and allowed to acclimatize for 2 weeks. All the animals received water and food ad libitum. After 5 weeks of a normal chow diet regimen, the animals were sacrificed and liver tissues from these animals were collected in RNAlater (Thermo Fisher, Waltham, USA).
PCR amplification and molecular cloning of rat Hmgcr promoter
The genomic DNA isolated from SHR and WKY liver tissues was PCR-amplified by Phusion TM High-Fidelity DNA polymerase (Finnzyme, USA) using the following primers: forward, FP-RatHMGCR-1KbPro: 5'-CGGGGTACCGTGGGTAGGTATATCCGGGCT-3' and reverse, RP-RatHMGCR-1KbPro: 5'-CCGCTCGAGAGCCACCTCGTGGAACCAGG-3'. KpnI and XhoI sites were added to the forward and reverse primers, respectively which are underlined and indicated in bold. The purified PCR-amplified promoter fragments (~1 kb) were cloned between KpnI and XhoI sites in firefly luciferase reporter vector pGL3-Basic (Promega, USA). The resulting plasmids were named as SHR-Hmgcr and WKY-Hmgcr which contain -985 bp to +20 bp region of SHR and WKY Hmgcr promoter sequence, respectively. Here, the cap site indicates +1 position and the numberings of the nucleotide positions are with respect to the cap site. The resultant Hmgcr-promoter-reporter plasmids were confirmed by sequencing using RV3 (5'-CTAGCAAAATAGGCTGTCCC-3') and GL2 (5'-CTTTATGTTTTTGGCGTCTTCCA-3') primers.
Sequencing and analysis of the Hmgcr promoters
The sequence of approximately ~1 kb Hmgcr promoter domains from SHR and WKY rats was determined by Sanger sequencing of the promoter plasmids followed by multiple sequence alignment using ClustalW (17) . The Hmgcr promoter regions harbouring polymorphisms were analyzed to predict putative transcription factor binding sites using online tools viz. ConSite (18) , TFSEARCH (19) , P-Match (20) and LASAGNA (21) at 65-95% cut-offs.
The Hmgcr promoter domains from different mammals harbouring the identified variations were mined from UCSC genome browser. The conservation of nucleotides in regions harbouring the polymorphisms across various mammals was aligned and analyzed using GeneDoc (22) .
Generation of site-directed mutations at SHR/WKY-Hmgcr promoter regions harbouring polymorphisms
In order to identify functional polymorphisms in the SHR/WKY Hmgcr promoter domains, mutations were generated at the regions of interest by site-directed mutagenesis using the SHR/WKY promoter construct as template and a primer pair with the desired mutation ( Table 1 ). The resulting promoter mutants were named as S405, W394, SDM, S62 and W62 ( Fig.4A ). The authenticity of these mutations was confirmed by sequencing.
Tissue-specific expression of HMGCR, SREBF1 and RUNX3
HMGCR, RUNX3 and SREBF1 expression data in various human tissues was mined from the EMBL-EBI expression atlas (http://www.ebi.ac.uk/gxa; Table 2 ) and GTEx portal (https://gtexportal.org/home/; Table S2 ). Those tissues which exhibited at least 10% HMGCR expression compared to that of the ovary with the highest TPM (82) and TPM cut-off of at least 1 for SREBF1 and RUNX3 were selected from the EMBL-EBI expression atlas for analysis. Likewise, tissue samples showing TPM of at least 1 for SREBF1 and RUNX3 were shortlisted from the GTEx portal. In another set of experiments, 0.5-1.0 µg/well of SHR/WKY promoter mutants were also transfected in BRL 3A cells. pCMV-βGal (β-galactosidase expression plasmid) was used as internal control for transfection efficiency. After 24 hrs of transfection, cells were lysed for luciferase and β -gal assays. The luciferase assay was carried as previously described (24) (25) (26) .
Cell culture, transient transfections and reporter assays
The normalized promoter activities were expressed as luciferase/β-gal reading. For cholesterol depletion, BRL 3A cells (transfected with SHR/WKY-Hmgcr promoter construct) were treated with 5 mM of cholesterol-depleting reagent methyl-βcyclodextrin (HiMedia, Mumbai, India) for 15 min. Cholesterol depletion was carried out in serum-free DMEM medium. Following cholesterol depletion, media was changed with fresh serum-free media and the cells were incubated for 6-9 hrs at 37°C in CO 2 incubator. In another series of experiments, promoter construct (SHR/WKY-Hmgcr)-transfected BRL 3A cells were treated with exogenous cholesterol (20 µg/ml) in serum free media for 6-9 hrs.
Following treatments, the cells were lysed for luciferase and Bradford assays.
Isolation of RNA from SHR/WKY liver tissues and real-time PCR analysis
Total RNA was isolated from liver tissues of SHR and WKY (4-6 weeks old) using the TRIzol reagent (Invitrogen, Waltham, USA) followed by purification using Nucleospin columns (Machery-Nagel, Duren, Germany). cDNA synthesis was performed using High For normalization of Hmgcr expression, GAPDH abundance was measured using the following primers: forward, 5'-GACATGCCGCCTGGAGAAAC -3' and reverse, 5'-AGCCCAGGATGCCCTTTAGT-3'. Hmgcr expression was normalized to GAPDH abundance and fold difference between SHR and WKY tissues was calculated by 2 -∆∆C t method (28) .
Chromatin Immunoprecipitation (ChIP) Assays
In order to confirm differential interactions of Runx3 and Srebf1 with the SHR-and WKY-Hmgcr promoters in vivo in context of chromatin, ChIP assays were carried out as described recently (29 
Western Blotting
For Western blot analysis, cells were lysed in radio-immunoprecipitation assay (RIPA) buffer following blocking with 3-5% of BSA/non-fat milk for 1 hr at room temperature. After 3 washes with 1xTBST, the membranes were incubated with HRP-conjugated secondary antibody specific for either rabbit (BioRad # 170-6515 at 1:3000 dilution for Hmgcr and Runx3) or mouse (Jackson Immunoresearch, West Groove, USA # 115-035-003 at 1:5000 dilutions for β -Actin, Vinculin and at 1:3000 for Srebf1) for 1 hr. The signals were detected using Clarity TM Western ECL Substrate kit (Bio-Rad, Hercules, USA) and a ChemiDoc
Chemiluminescence Detection system (Bio-Rad, Hercules, USA). The intensities of signals/bands were quantified using ImageJ (30) .
Filipin staining of BRL 3A cells
BRL 3A cells (transfected with SHR/WKY-Hmgcr promoter construct) were treated with 20 µg/ml of exogenous cholesterol (HiMedia, Mumbai, India) or 5mM of cholesterol-depleting reagent methyl-β-cyclodextrin (MCD; HiMedia, Mumbai, India) for 6 hrs or 15 min, respectively. The media was changed to serum-free media following MCD treatment and the cells were incubated at 37 °C for 6-9 hrs. The cells were then washed with PBS and fixed with 3.6% formaldehyde in PBS for 10 min at room temperature. Following fixation, the cells were washed with PBS thrice and stained with 50 µg/ml of Filipin III (a fluorescent dye binding to free cholesterol) in the dark at room temperature for 3 hrs. The stained cells were imaged using an Olympus IX73 fluorescence microscope (Olympus, Tokyo, Japan).
Analysis of serum cholesterol and systolic blood pressure values from various genetically-inbred hypertensive strains
The serum total cholesterol and systolic blood pressure data from different genetically-inbred hypertensive strains along with their respective normotensive control values was obtained from the National BioResource Project-Rat (http://www.anim.med.kyoto-u.ac.jp/nbr/) and PhenoMiner tool of the Rat Genome Database (http://rgd.mcw.edu/rgdweb/search/qtls.html?100). The identity of the strains (n=21) and related information is mentioned in Table 3 .
Data presentation and statistics
All transient transfection experiments were performed at least three times and results were expressed as mean ± SEM of triplicates. Statistical significance was determined by Student's t-test or one-way ANOVA with Newman-Keuls's post-test, as appropriate for different experiments using Prism 5 program (GraphPad Software, San Diego, CA, USA). GraphPad Prism 5 software was used to generate all the graphs.
RESULTS
Comparative genomics analysis of human, mouse and rat Hmgcr gene sequences.
Although various resources are available for genetic mapping in mice and mouse models are highly useful to dissect the genetic basis of complex human diseases (31) , most of the quantitative trait loci (QTL) studies have been performed in rats because measurement of cardiovascular phenotypes in mice is technically challenging. We probed the Rat Genome Database (RGD) (15) for blood pressure QTLs on Hmgcr-harbouring chromosome 2 and detected several blood pressure QTLs (Fig.1A) . The blood pressure-QTLs, their positions and respective LOD [logarithm (base 10) of odds] scores retrieved from RGD are shown in Table   S1 . Interestingly, the QTL Bp240 (45317613-103494306 bp) that harbours Hmgcr gene (27480226-27500654 bp, RGD ID: 2803) displayed the highest linkage (LOD score=4.0) with mean arterial blood pressure and systolic blood pressure ( Fig.1A ). In addition, QTLs-Bp243 (45317613-155139446 bp), Bp205 (45399390-62179292 bp) also housing the Hmgcr locus displayed significant linkage with diastolic blood pressure (LOD score=3.9) and
mean arterial blood pressure (LOD score=3.476), respectively. Moreover, alignment of the mouse and human genomic regions with the orthologous rat sequences at Hmgcr locus using mVISTA showed >75% homology between the rodent sequences at exons, introns and untranslated regions (Fig.1B) ; the human genomic regions show high conservation at the 5'
UTR and exonic regions with the rat sequences. In general, the extent of homology between each of the twenty Hmgcr exons in mouse and rat was higher (>85%) than the noncoding regions ( Fig.1B) . Thus, rat Hmgcr appeared as a logical candidate gene for studying the mechanisms of hypertension.
Hmgcr is differentially expressed in SHR and WKY liver tissues.
To investigate whether the expression of Hmgcr differs between SHR and WKY in liver tissues, we assessed the Hmgcr mRNA and protein levels in the liver (primary site for cholesterol biosynthesis). Our qPCR analysis revealed that the Hmgcr transcript levels were elevated in liver tissues of WKY (~4-fold, p<0.05; Fig.2A ) as compared to SHR. In corroboration, the Hmgcr protein level were also higher in WKY liver issues as compared to SHR (~by 2-fold, p<0.05; Fig.2B ).
Identification of variations in the SHR/WKY-Hmgcr promoter domain and
conservation of nucleotide sequences at the polymorphic regions among different mammals.
To unravel the molecular mechanism of differential expression of Hmgcr between SHR and WKY, the proximal ~1 kb region of the Hmgcr promoter domain was sequenced in these models. ClustalW (17) alignment of the SHR-and WKY-Hmgcr promoter sequences revealed three variations: A-405G, C-62T and a 11 bp insertion (-393_-382insTGCGGTCCTCC) in SHR-Hmgcr promoter with respect to WKY-Hmgcr promoter ( Fig.2E ).
To analyse if there is any conservation across the polymorphic domains of the rat
Hmgcr promoter with orthologous Hmgcr sequences in various mammalian species, the SHR/WKY promoter sequences were aligned with the Hmgcr promoter sequences of various mammals (mouse, human, rat, orangutan, pig and cow) using the GeneDoc software (22) .
Interestingly, the G-allele at -405 bp position discovered in SHR was conserved at the corresponding positions in Hmgcr promoter of mouse, human, orangutan, pig and cow ( Fig.3A) . However, the -393_-382insTGCGGTCCTCC was observed only in SHR among the sequences included ( Fig.3A) . Additionally, the T-allele at the -62 bp position in SHR was absent in the other mammals included in this analysis ( Fig.3B ).
Differential activities of Hmgcr promoters under basal conditions.
To To access if the variations identified in the SHR/WKY-Hmgcr domains were functional, various Hmgcr promoter mutants were generated by site-directed mutagenesis (Fig.4A ). The
Hmgcr promoter constructs (viz. SHR, WKY, SDM, W394, S62, W62 and S405) and the pGL3-basic plasmid (as control) were transfected into BRL 3A and HuH-7 cells (Fig.4) .
Interestingly, the W394 and S62 constructs showed diminished promoter activity as compared to the WKY-Hmgcr promoter in both BRL 3A and HuH-7 cell lines (p<0.01). This suggests that the G allele at -405 bp position and -393_-382insTGCGGTCCTCC in SHR-Hmgcr promoter may contribute to the diminished promoter activity of SHR-Hmgcr promoter. However, the contribution of the variation at the -62 bp to the overall basal Hmgcr promoter activity of SHR or WKY was uncertain as both S62 and W62 constructs showed no significant difference with SHR and WKY-Hmgcr promoter activity, respectively, in both the cell lines tested. Therefore, differential activities of SHR/WKY-Hmgcr promoters may be due to the allele at -405 bp position and the insertion at -393/-382 bp position.
Since we identified variations in the SHR/WKY-Hmgcr promoter domains, we carried out stringent in silico analysis to identify potential transcription factors that may alter the expression of Hmgcr in these models of EH. Computational analyses were carried out using four different tools to predict the putative transcription factor binding sites: ConSite Hence, Runx3 and Srebf1 were selected for further experimental studies.
Important roles of Runx3 and Srebf1 in transcriptional regulation of Hmgcr.
To test the effect of predicted transcription factors (Runx3 and Srebf1) on Hmgcr gene regulation, we carried out co-transfection experiments in BRL 3A cells. Over-expression of Runx3 caused a dose-dependent reduction in the SHR-Hmgcr promoter activity (~up to 2fold, p<0.01); the WKY-Hmgcr activity was also dose-dependently diminished (~up to 1.8~fold, p<0.001) under similar conditions (Fig.5A) . The SHR-Hmgcr promoter activity, in general, was lower than the WKY-Hmgcr promoter activity at each concentration of Runx3 to IgG) ( Fig.5B) . Moreover, the fold-enrichment of the SHR-Hmgcr domain was significantly higher for immunoprecipitation with Runx3 as compared to WKY-Hmgcr domain (by ~1.5fold, p<0.01; Fig.5B ).
Similarly, co-transfection of Srebf1 augmented the SHR-Hmgcr promoter activity (up to ~3.7-fold, p<0.001) and WKY-Hmgcr promoter activity (up to ~3.8-fold, p<0.001) in a concentration-dependent manner (Fig.5C ). Interestingly, ChIP assays displayed enhanced enrichment of WKY-Hmgcr domain (up to ~2-fold, p<0.001 with respect to IgG) for immunoprecipitation with Srebf1 (Fig.5D ). In contrast, there was no significant enrichment of the SHR-Hmgcr domain with respect to IgG (Fig.5D ). Taken together, these results suggest that Runx3 exerts stronger interactions with SHR-Hmgcr promoter than the WKY-Hmgcr promoter while Srebf1 binds to WKY-Hmgcr promoter with higher affinity as compared to the SHR-Hmgcr promoter.
Association of Hmgcr expression with Runx3 and Srebf1 levels in rat models of hypertension and human tissues.
In view of our findings of modulation of Hmgcr promoter activity by Runx3 and Srebf1, we investigated the Runx3 and Srebf1 protein levels in liver tissues of SHR and WKY. Western blot analysis showed enhanced Runx3 protein levels (up to ~5-fold, p<0.0001) in SHR liver tissues as compared with WKY ( Fig.6C ). On the other hand, the Srebf1 protein levels were reduced (up to ~8-fold, p<0.0001) in SHR as compared to WKY in the liver (Fig.6D) .
In order to extent our findings to human tissues, correlation analysis was performed between HMGCR and RUNX3/Srebf1 transcript levels in various human tissues using two expression databases. The transcript level of HMGCR showed no correlation to the RUNX3 expression in human tissues (Fig.6E, S1A ). However, correlation analysis between transcript levels of HMGCR and SREBF1 across various human tissues revealed a significant positive correlation (Pearson r = 0.6395, p = 0.02 for EMBL-EBI expression data, Fig.6F ; Pearson r = 0.5437, p = 0.003 for GTEx Portal data, Fig.S1B ) suggesting a key role of Srebf1 in HMGCR regulation.
Intracellular cholesterol modulates Hmgcr expression via Runx3 and Srebf1.
As Hmgcr protein level is influenced by intracellular cholesterol level and regulated by a negative feed-back mechanism (6) we sought to determine whether modulating the endogenous cholesterol level affects SHR/WKY-Hmgcr promoter activity. Accordingly, BRL 3A cells transfected with SHR-and WKY-Hmgcr promoter constructs were treated with either cholesterol (20 µg/ml) or methyl-β-cyclodextrin (MCD, a cyclic oligosaccharide that reduces intracellular cholesterol level; 5 mM) ( Fig.7A, B) . Indeed, exogenous cholesterol treatment diminished both the SHR (by ~1.9-fold, p<0.05) and WKY-Hmgcr promoter activities (by ~3-fold, p<0.0001) (Fig.7A ). In corroboration, intracellular cholesterol depletion enhanced both the SHR (by ~2.5-fold, p<0.05) and WKY-Hmgcr promoter activities (by ~1.62-fold, p<0.05) (Fig.7B) . The increase/decrease in the intracellular cholesterol level upon cholesterol treatment/depletion experiments were confirmed by Filipin staining (Fig.S2) . Western blot analysis revealed that the endogenous Hmgcr protein level 
Inverse correlation of serum cholesterol levels and systolic blood pressure in rat models of hypertension.
Consistent with diminished Hmgcr promoter activity and Hmgcr mRNA/protein expression in SHR as compared to WKY, the serum cholesterol level of SHR is also reduced in comparison to WKY (Fig.S3) . In order to test if other genetically-inbred hypertensive rat strains also show diminished serum cholesterol levels with respect to their controls, we retrieved serum total cholesterol and systolic blood pressure values of 21 strains from the (Table 3) . Interestingly, the serum cholesterol level and systolic blood pressure showed a significant negative correlation (Pearson r = -0.6475, p = 0.0015; Fig.S4 ) across various genetic rat models of hypertension suggesting that reduction in serum cholesterol levels might be a common compensatory mechanism in response to elevated blood pressure in these strains.
DISCUSSION
Overview.
Dyslipidemia is a strong predictor of cardiovascular diseases including hypertension, obesity, atherosclerosis, coronary artery disease, and type 2 diabetes (32) (33) (34) . HMGCR, a key regulator of dyslipidemia, is targeted by statins to lower high cholesterol levels and risk of CVDs (35, 36) . Several studies also reported associations of single nucleotide polymorphisms (SNPs) in the HMGCR locus (viz. rs12654264, rs3846662, rs7703051, rs5908 rs12916, rs17238540 and rs3846663) with level of total cholesterol, LDL cholesterol and risk for dyslipidemia/stroke/blood pressure and coronary heart disease (37) (38) (39) (40) (41) (42) (43) (44) . Despite such associations of Hmgcr with lipid homeostasis and cardiovascular pathophysiology, the transcriptional regulation of Hmgcr in rat models of essential hypertension which are routinely used to investigate the molecular mechanisms underlying CVDs, has not been investigated. In this study, we found that Hmgcr is differentially expressed in liver tissues of these hypertensive rat models. Furthermore, sequencing and systematic experimental analyses revealed functional genetic variations (viz. A-405G and -393_-382insTGCGGTCCTCC) that altered the binding affinities of Runx3 and Srebf1 for SHR and WKY-Hmgcr promoters thereby resulting in diminished SHR-Hmgcr promoter activity as compared to WKY (Fig.3) . The variant G allele at -405 bp in SHR was also detected in corresponding Hmgcr sequences of various mammals suggesting the preservation/occurrence of this variation in the course of evolution (Fig.3 ).
Molecular basis of modulated Hmgcr expression: Role of Runx3 and Srebf1.
In the view of differential expression of Hmgcr in SHR/WKY liver tissues (Fig.2) , do variations A-405G and -393_-382insTGCGGTCCTCC alter the Hmgcr promoter activity?
Computational analysis revealed that the G allele at the -405 bp and insertion at -393/382 bp in SHR-Hmgcr promoter offered better binding sites for Runx3 as compared to the A allele ( Fig.4D ). On the other hand, the A allele at -394 bp in WKY-Hmgcr promoter harboured a stronger Srebf1 binding site as compared to the G allele.
Runt-related transcription factor 3 (Runx3), a transcription factor belonging the Runtrelated transcription factor family, is abundantly expressed in the hematopoietic system and involved in a variety of physiological processes including B-cell/T-cell differentiation, development of gastrointestinal tract and dorsal root ganglia neurogenesis (45, 46) .
Consistent with our in silico predictions, over-expression of Runx3 reduced the SHR-Hmgcr promoter activity to a greater extent than the WKY-Hmgcr promoter activity (Fig.5A) . In In line with the reported role of Srebf1 in Hmgcr expression (50) and our computational analyses, ectopic expression of Srebf1 caused a pronounced enhancement in the WKY-Hmgcr promoter activity than the SHR-Hmgcr promoter (Fig.5C ). The differential binding of Srebf1 was confirmed by ChIP assays (Fig.5D ). Sterol-regulatory element-binding protein 1 (SREBP-1) or Srebf1, encoded by Srebf1 gene, has two protein isoforms that are well known transcription factors regulating hepatic cholesterol and fatty acid synthesis (50) .
Of note, over-expression of SREBPs in rodents causes hepatic steatosis and a transgenic SHR strain over-expressing human SREBP-1a exhibits multiple features of metabolic syndrome including hypertriglyceridemia, hyperinsulinemia and hypertension along with hepatic steatosis (51) . Interestingly, genetic variations in SREBP have been reported to be associated with various cardiovascular complications in humans (52, 53) . Does SHR show diminished hepatic level of Srebf1 contributing to the overall decrease in the Hmgcr protein and mRNA levels? Indeed, Western blot analysis reveals reduced Srebf1 level in SHR than WKY liver tissues ( Fig.6A, D) . This is in corroboration with a study that reported genetic variants in Srebf1 gene in SHR account for lower Srebf1 mRNA/protein levels and Srebf1 promoter activity (54) .
In light of the role of Runx3 and Srebf1 in the transcriptional regulation of rat Hmgcr, we asked if the levels of Hmgcr and these transcription factors in human tissues correlated?
Indeed, the HMGCR and SREBF1 transcript levels were significantly positively correlated across various tissues of human origin (Fig. 5F, S3B) suggesting that SREBF1 could regulate HMGCR expression in human tissues. On the other hand, RUNX3 transcript levels showed a negative correlation with HMGCR transcripts levels which was not significant (Fig.6E ). This observation is consistent with the dual role of RUNX3 as an activator as well as a repressor in different tissues (47-49, 55-57) (Fig.7A, B) . What could be the molecular mechanism of this response to cholesterol level by these promoters? Since Runx3 and Srebf1 are involved in the differential expression of SHR and WKY-Hmgcr promoters under basal conditions, we probed their levels upon modulating the intracellular cholesterol level. Interestingly, the Runx3 protein level was also modulated upon cholesterol treatment/depletion (Fig.7E ).
Regulation of Hmgcr expression under pathophysiological conditions by
Consistent with previous reports, the Srebf1 level was enhanced/reduced when cholesterol was diminished/augmented ( Fig.7F) 
Rat models of hypertension show diminished serum cholesterol levels.
In line with the enhanced Hmgcr mRNA and protein levels in liver tissues of WKY than SHR ( Fig.1) , multiple studies reported elevated plasma and hepatic cholesterol levels in WKY as compared to SHR (60, 61) . We speculate that the differential expression of Hmgcr, resulting in altered serum cholesterol levels, may be a sex-independent phenomenon since SHR strains show similar fold-diminishment (~1.4-fold, Fig.S3 ) in serum cholesterol levels with respect to their sex-matched WKY controls. Thus, SHR emerges as a model where dyslipidemia and hypertension do not seem to be inter-connected. This is not surprising as these animals were derived solely based on high blood pressure as the selection criteria (10, 11) possibly resulting in segregation of genes. This is reminiscent of a previous study that revealed diminished hepatic Hmgcr expression and plasma cholesterol level in genetically hypertensive BPH (blood pressure high) mice as compared to hypotensive BPL (blood pressure low) mice (8) . Additionally, chromogranin A gene knock out mice which displayed severe hypertension, also showed enhanced Hmgcr mRNA level than their wild-type control mice (62) . These studies highlight the possibility that modulated Hmgcr expression might be a crucial aspect of hypertension and associated cardiovascular complications in mammals.
Indeed, serum cholesterol and systolic blood pressure levels displayed a significant inverse correlation (Fig.S4 ) across various genetically-inbred hypertensive rat strains. We speculate that the decrease in serum cholesterol levels might be a compensatory response to elevated blood pressure in these genetic models of hypertension thereby, alleviating further risk of cardiovascular complications.
Conclusion and perspectives.
This study identified two functional promoter variations in rat models of human essential hypertension that regulate Hmgcr expression by altering the binding affinity of Srebf1 and Runx3 with Hmgcr promoter under basal and pathophysiological conditions. Our overall observations are shown by a schematic representation (Fig.8) . Notably, the expression pattern of HMGCR and SREBF1 correlated well in various human tissues. However, additional investigations are required to unravel the functional implications of these variations for hypertension. Nonetheless, this is the first report on identification and functional characterization of polymorphisms in the Hmgcr locus in hypertensive SHR vs. normotensive WKY. Our findings also reveal that multiple genetic rodent models of hypertension (apart from SHR) exhibit diminished serum cholesterol levels possibly as a protective mechanism to attenuate further cardiovascular complications. Future studies may provide novel insights into molecular links of Hmgcr with hypertension and other cardiovascular disease states. 
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